Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Exactly. I'm not gonna waste any more post on the old stuff. Let's focus on the stock only.
Revenues were $1.4M for 9 months for online channels only. Imagine how much revenues NNRX will generate once its products get rolled out to the local and national retail chains. It will be massive.
Exactly. All we care about is the future of NNRX which is pretty bright.
Who cares he is a CEO right now. Not a practicing Doctor. Your pulling irrelevant info out cause you have nothing
Can a Doctor be both active Surgeon and CEO of a public company at the same time?
Old news...We have discussed about this on 10/13 after the 8-K came out. I'm sure you also have noticed that there has been no dilutive MM on the asks since Dr. Joe Eyring arrived. Things have changed since Dr. Joe Eyring took over the CEO position. Almost all of the investors here including myself are investing into the future of NNRX because we could careless about its past.
Think of it this way. The old NNRX used to be like a football team with a handicap quarterback which he couldn't throw nor run the football. Because of that the team was winless and the fans abandoned them. The team replaced the quarterback with the new one. The new NNRX hires a great quarterback who knows how to work the offensive line. The team starts winning games and the fans start following them.
"Our stock has suffered over the last year. News and updates were scattered due to ongoing declines in sales to new customers and our lack of new products developed for the billion-dollar nutraceutical market in which we compete. Our stock price continually retreated due to the financing structures once available to us to pay for mandatory public market costs and listing requirements. Maintaining our listing, reporting and compliance remained important to us and critical to our shareholders. It is for this reason, I am addressing you today. We qualified and quantified each of the financings which may have dilutive effects in the future. I say "may" because it is our intent to pay them off if possible, all of them, with capital I plan to personally inject into NNRX in the coming weeks. I cannot disclose more of these details but certainly will in an 8-K and press release as appropriate."
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=117705371
Notes due now
On October 18, 2013, the Company issued a convertible note to an unrelated party for $125,000 that matures in October 18, 2015. The note bears an interest rate of 10% per annum with a floor of $.005 per share, and principal is convertible at any time after October 18, 2013 in part or in whole into shares of the Company's common stock using the average closing prices for five trading days directly preceding the conversion date. Interest is not convertible and is due upon conversion or at the maturity date.
On November 22, 2013, the Company issued a convertible note to an unrelated party for $150,000 that matures in November 22, 2015. The note bears an interest rate of 10% per annum with a floor of $.005 per share, and principal is convertible at any time after November 22, 2013 in part or in whole into shares of the Company's common stock using the average closing prices for five trading days directly preceding the conversion date. Interest is not convertible and is due upon conversion or at the maturity date.
Hi Lone Wolf,
Could you please sticky post #5419?
Thanks, Bud.
Hi SPORTYNORTY,
Could you and/or someone else please PM the other 5 unactive Mods and ask them to politely resign their spots if they are no longer interested in NNRX so that new investors can replace theirs.
Thanks,
Win
NNRX ALL-IN-ONE DUE DILIGENCE
October 1, 2015, Dr. Joe Eyring, the new CEO, came on board.
http://ih.advfn.com/p.php?pid=nmona&article=68767027
October 14, 2015, Dr. Joe Eyring issued Shareholder Letter.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=117705371
Revenues for the first 9 months were $1,345,110 with Gross Profits were $685,731.
http://ih.advfn.com/p.php?pid=nmona&article=67719385
The bottom line will look even better in the future with cost cutting measures:
"The day I assumed office, I dismissed underperforming staff, began scripting an employee handbook, defined job requirements and reviewed the balance of W-2 versus 1099 staff. In the weeks after, we audited our supply chain, manufacturing, inventory, pricing and reviewed credit lines for customers and our own with our creditors and banks. We cut, trimmed, streamlined and found savings never before realized. Our work resulted in significant reductions of operating costs, and in one such case, we found an available cost reduction of 30% on our leading products. We expect to realize these financial benefits and others in the coming quarters."
GenEpic PBS Special & Other Links
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=118032527
NNRX's Products Can Be Bought Here:
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=118032561
Future News to look forward to:
1) Dr. Joe Eyring to inject his own money into NNRX. This could come out at any moment now.
"We qualified and quantified each of the financings which may have dilutive effects in the future. I say "may" because it is our intent to pay them off if possible, all of them, with capital I plan to personally inject into NNRX in the coming weeks. I cannot disclose more of these details but certainly will in an 8-K and press release as appropriate."
2) Sale orders News coming out of Asia.
"We negotiated an exclusive worldwide license for GenEpic® and refocused Dr. Gibbs onto OEM and formulation sales. At this moment, Dr. Gibbs is in Asia actively securing orders for our OEM and Formulation Division."
Pictures of Dr. Gibbs currently in Japan
https://www.facebook.com/GenEpic.in.Japan/photos_stream
3) Distribution deals to bring NNRX's products to local and national retail chains.
4) Updates on Cancer treatments.
https://www.facebook.com/Nutranomicsinc
Share Structure from TA
A/S = 750,000,000
O/S = 481,780,758
Float = 380,000,000 (Dr. Gibbs' and former CEO's funds hold almost 100,000,000)
New investors, please apply for the Mod spots. I'm the only one active and I can't sticky more than 1 note.
Hi BlackSnake1,
I appreciate your looking out for me. I know what I'm doing because I don't follow people. I only follow the companies. Before I invest my money in any particular company, I would spend a lot of time going through its financial reports looking at revenues, profit margin, expenses, capital structures...etc. I also spend time researching the company's products, affiliations, partners...etc. Last but not least, I always communicate with the company first before I invest.
Since Dr. Joe Eyring took over NNRX, it offers everything that I have been looking for.
Traders, investors, pumpers, bashers...etc will come and go, but I'll still be here until my target is met.
Regards,
Win
Hi Lone Wolf,
Could you please sticky my post #5282?
Thanks,
Win
Nutranomics, Inc. Issues Shareholder Letter
Newly-Appointed, CEO and President, Dr. Edward "Joe" Eyring Details Immediate Actions and Improvements to Operations
DRAPER, UT -- (Marketwired) -- 10/14/15 -- Nutranomics, Inc. (OTC PINK: NNRX) ("Nutranomics" or "The Company"), a diversified nutraceutical formulator, supplement manufacturer and marketer of Nutranomics® health supplements, today issued a Shareholder Letter (the "Letter"). The Letter details challenges the Company endured during the last year, reports operational improvements to date, establishes strategies to regain sales momentum and provides options to finance the Company's growth.
Re: NNRX Shareholder Letter
Date: October 14, 2015
From: Dr. Edward "Joe" Eyring
Valued Shareholders,
I would like to acknowledge and thank those who wrote or spoke the words of support received after my appointment to CEO and President of Nutranomics, Inc. My intent is to continue to gain your trust over successive quarters as we rebuild our core business segments and reinvigorate others. I believe the plans and goals we have established as a team will result in revenue and earnings growth, an increase in the value of our stock and the ability to regain shareholders' and the market's confidence. All of these are typical CEO goals, but the skill for us to accomplish them is ultimately found in our operations as a company. For this reason, this letter focuses on this first and foremost.
As stated in the announcement last week, my work with Nutranomics included a three-month process during which time the Company provided me access to management, staff, customers, financials and suppliers. Dr. Tracy Gibbs and then Michael Doron each had solid business plans for the Company during their tenures, but I believe both gentlemen would agree that the Company's inability to achieve them detracted attention from that which Nutranomics should always do best. This is the researching, formulation, manufacturing, and marketing of Nutranomics®and GenEpic®-branded products plus securing NNRX formulation and OEM contracts. The forces that were preventing us from this core objective were many, but can be categorized by; ineffective sales and marketing plans, misaligned staffing, lack of manufacturing cost controls, pricing models which prevented us from being competitive and finally, poor cash flows as a direct result of the conditions above. After a decade of fast-growth, NNRX plateaued and was in decline. However, at its core was a committed team of employees devoted to the Company, its brand, and its mission to provide one of the best nutraceutical product lines to a growing list of customers worldwide. With this belief, I assumed an active management role in the Company.
The day I assumed office, I dismissed underperforming staff, began scripting an employee handbook, defined job requirements and reviewed the balance of W-2 versus 1099 staff. In the weeks after, we audited our supply chain, manufacturing, inventory, pricing and reviewed credit lines for customers and our own with our creditors and banks. We cut, trimmed, streamlined and found savings never before realized. Our work resulted in significant reductions of operating costs, and in one such case, we found an available cost reduction of 30% on our leading products. We expect to realize these financial benefits and others in the coming quarters.
This was good news, but as mentioned above, if we could not leverage sales growth in this new paradigm, all the process efficiencies and cost saving measures would not benefit our shareholders. We then looked at every aspect of our product lines and their sales. We endeavored to complete a new order processing and CRM system to market, sell, deliver and service our customers. We studied customer purchasing patterns and trends in the market and engaged the Hamacher Group to update our brand and positioning for our current and future products we will launch. We negotiated an exclusive worldwide license for GenEpic® and refocused Dr. Gibbs onto OEM and formulation sales. At this moment, Dr. Gibbs is in Asia actively securing orders for our OEM and Formulation Division.
Our last 10-Q showed the decline in year-over-year sales we must reverse first and before we enter our next growth stage. This need is critical for our staff, our shareholders and our customers. For those of you who reviewed the terms of my employment contract disclosed in our recent Current Report on Form 8-K filed with the SEC, I am also staking my compensation directly on measured increases in sales. I believe the plans above will help us meet them.
Our stock has suffered over the last year. News and updates were scattered due to ongoing declines in sales to new customers and our lack of new products developed for the billion-dollar nutraceutical market in which we compete. Our stock price continually retreated due to the financing structures once available to us to pay for mandatory public market costs and listing requirements. Maintaining our listing, reporting and compliance remained important to us and critical to our shareholders. It is for this reason, I am addressing you today. We qualified and quantified each of the financings which may have dilutive effects in the future. I say "may" because it is our intent to pay them off if possible, all of them, with capital I plan to personally inject into NNRX in the coming weeks. I cannot disclose more of these details but certainly will in an 8-K and press release as appropriate.
Since we have received a number of comments and questions from shareholders on the potential action to reverse split our shares, let me provide you our insights. Our consideration of such was not a shareholder request recover additional, dilutive share issuances only to issue more shares. Rather, this consideration was an effort to position our stock to meet listing requirement on OTC Markets' QB and other National Exchanges like Nasdaq and NYSE. We believe we will obtain greater access to investors and potentially institutional investors with a cap structure and share price greater than current pricing.
This, however is down the road at best. For now, the below is our basic plan;
1. Rebuild Nutranomics' sales and communicate our efforts
2. Diminish or eliminate dilutive financing structures currently in place
3. Finance our business with new capital
4. Report our successes each step of the way
I hope this initial communication has answered many of the questions asked of us over the last two weeks. While I always want to be shareholder-responsive, I have also enlisted the help of other seasoned professionals to do the same. I will speak to all of our shareholders in consistent intervals on conference calls, press and at investor events. When not doing so, I will be out getting orders and building our business with our new sales team. For this reason, please engage with our shareholder communications contacts and others below also charged to service your questions and requests.
We value your ownership of NNRX shares and appreciate your support of the actions and plans detailed in this letter to you. We will be back in touch, and more frequently, from this point onward.
Sincerely,
Dr. Edward "Joe" Eyring, M.D.
About Nutranomics Inc.
Nutranomics, Inc. (OTC PINK: NNRX) has been at the forefront of research and development of nutritional food products since its inception in 1995. In the first years of its operations, Nutranomics provided research and development of supplement formulations and nutraceuticals for domestic and international brands. After developing 100's of successful formulations and patents, Nutranomics developed its own brand of nutraceuticals in 1997, Nutranomics®, and began to market and sell its products directly to consumers and into retail outlets. Nutranomics maintains customers in the US, Canada, Taiwan, Japan, Singapore, Malaysia, Korea and Poland.
More than just a health supplement manufacturer, Nutranomics supports the worldwide community of people aiming for a healthy lifestyle by making education a core business philosophy.
Forward-Looking Statements:
Safe Harbor: This press release contains forward-looking information within the meaning of section 27A of the Securities Act of 1933 and section 21E of the Securities Exchange Act of 1934 and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Nutranomics Inc., to be materially different from the statements made herein.
For the Company:
Matt Crowley Controller NURTANOMICS, INC. (OTC PINK : NNRX)
11487 S. 700 E
Draper, UT 84020
e: matt@nutranomics.com
p: (801) 576-8350
f: (801) 619-9060
w: www.nutranomics.com
Investor relations contact: John Mattio
Lamnia International for:
Nutranomics, Inc.
e: jmattio@lamniaintl.com
p: (203) 885-1058
w: www.lamniaintl.com
Source: Nutranomics Inc.
NNRX ALL-IN-ONE DD
October 1, 2015, Dr. Joe Eyring, the new CEO, came on board.
http://ih.advfn.com/p.php?pid=nmona&article=68767027
October 14, 2015, Dr. Joe Eyring issued Shareholder Letter.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=117705371
Revenues for the first 9 months were $1,345,110 with Gross Profit $685,731.
http://ih.advfn.com/p.php?pid=nmona&article=67719385
The bottom line look even better in the future with cost cutting measures:
The day I assumed office, I dismissed underperforming staff, began scripting an employee handbook, defined job requirements and reviewed the balance of W-2 versus 1099 staff. In the weeks after, we audited our supply chain, manufacturing, inventory, pricing and reviewed credit lines for customers and our own with our creditors and banks. We cut, trimmed, streamlined and found savings never before realized. Our work resulted in significant reductions of operating costs, and in one such case, we found an available cost reduction of 30% on our leading products. We expect to realize these financial benefits and others in the coming quarters.
GenEpic PBS Special & Other Links
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=118032527
NNRX's Products Can Be Bought Here:
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=118032561
Future News to look forward to:
1) Dr. Joe Eyring to inject his own money into NNRX. This could come out at any moment now.
"We qualified and quantified each of the financings which may have dilutive effects in the future. I say "may" because it is our intent to pay them off if possible, all of them, with capital I plan to personally inject into NNRX in the coming weeks. I cannot disclose more of these details but certainly will in an 8-K and press release as appropriate."
2) Sale orders News coming out of Asia.
"We negotiated an exclusive worldwide license for GenEpic® and refocused Dr. Gibbs onto OEM and formulation sales. At this moment, Dr. Gibbs is in Asia actively securing orders for our OEM and Formulation Division."
Pictures of Dr. Gibbs currently in Japan
https://www.facebook.com/GenEpic.in.Japan/photos_stream
3) Distribution deals to bring NNRX's products to local and national retail chains.
4) Updates on Cancer treatment.
https://www.facebook.com/Nutranomicsinc
Share Structure from TA
A/S = 750,000,000
O/S = 481,780,758
Float = 380,000,000 (Dr. Gibbs' and former CEO's funds hold almost 100,000,000)
I'm at lunch. When I come back after lunch, I'll compose an all-in-one DD post for the new investors. Stay tuned.
We are dealing with the last of the profit takers. Once they're done, we will move up easily without much of a resistance.
Hi Bulls9999,
That goes to show how undervalue NNRX is currently. With Dr. Joe at the helm, I expect NNRX's revenues to be over $1,000,000 per quarter starting Q1 2016.
I can not believe this is market capped so low (~$500,000)....and it has $1 mill in sales as well?
Another stock (##RMHB##) is selling energy drinks, had a great quarter last quarter ($700k revenues) and has a pps of 0.09-0.10 lately, has about the same OS as NNRX, and market capped at a ridiculously high ~50 mill, WTH?
I think this stock is seriously low-balled, and should it show any type of commercial interest in it's products or successful application, the sky is the limit; and healthcare products/needs for people are financed by insurance.
Hi ErnieBilco,
Would you invest $500K of your own money into any of the company without some kind of protection?
It is never a good sign when insiders flee from commons and issue themselves equal shares protected by preferreds.
Wonder when the consolidation is gonna hit.
With strong bids support and weak thin asks, people who sold out will have to pay more to buy back in. NNRX has been on fire towards the end of the day as of late.
52 week high .06 cents. Funny whoever selling. I added more today :)
$NNRX
Extremely undervalue for a well established company with real, patented products that are being sold worldwide and bringing in good revenues with high profit margin. Moreover, the Share Structure is really low (OS=480M, AS=750M) for a sub stock. On top of that, NNRX just got a new CEO in place who is a Medical Doctor and entrepreneur. He's in the process of injecting his own money into NNRX to buy out all of its debt.
Therefore, once the news starts to flow, this can run to pennies pretty quickly.
Thanks for my Market Cap correction! WOW! So the current NNRX market cap is only about $600K. Unbelievable low! How many countries do they sell the patented product!? :)
Hi rjbluesky,
Your calculation is incorrect.
O/S = 480M
A/S = 750M
.005 x 480M = $2.4M
If we had a MC of $10M, the share price would be .0208.
Absolutely, and we know the CEO is not going to be diluting since he is paying off debt himself and has personal $s to support NNRX! Even at $.005, that's about a $10 mil market cap. But looking at all those countries they sell the Patented products in combined with a fairly low trading float, multi-pennies sound more like it IMO.
Love seeing the slow and steady move which builds a strong foundation one tick at a time.
Hi Crowin,
Have you noticed that NNRX just got a new CEO in place and he's going to inject his own money to buy out the NNRX's debt and among other things? Many of the investors including myself are invested here because we believe Dr. Joe can turn NNRX around based on his credentials and plans. NNRX is reborn with Dr. Joe at the helm.
Nutranomics, Inc. Issues Shareholder Letter
Newly-Appointed, CEO and President, Dr. Edward "Joe" Eyring Details Immediate Actions and Improvements to Operations
DRAPER, UT -- (Marketwired) -- 10/14/15 -- Nutranomics, Inc. (OTC PINK: NNRX) ("Nutranomics" or "The Company"), a diversified nutraceutical formulator, supplement manufacturer and marketer of Nutranomics® health supplements, today issued a Shareholder Letter (the "Letter"). The Letter details challenges the Company endured during the last year, reports operational improvements to date, establishes strategies to regain sales momentum and provides options to finance the Company's growth.
Re: NNRX Shareholder Letter
Date: October 14, 2015
From: Dr. Edward "Joe" Eyring
Valued Shareholders,
I would like to acknowledge and thank those who wrote or spoke the words of support received after my appointment to CEO and President of Nutranomics, Inc. My intent is to continue to gain your trust over successive quarters as we rebuild our core business segments and reinvigorate others. I believe the plans and goals we have established as a team will result in revenue and earnings growth, an increase in the value of our stock and the ability to regain shareholders' and the market's confidence. All of these are typical CEO goals, but the skill for us to accomplish them is ultimately found in our operations as a company. For this reason, this letter focuses on this first and foremost.
As stated in the announcement last week, my work with Nutranomics included a three-month process during which time the Company provided me access to management, staff, customers, financials and suppliers. Dr. Tracy Gibbs and then Michael Doron each had solid business plans for the Company during their tenures, but I believe both gentlemen would agree that the Company's inability to achieve them detracted attention from that which Nutranomics should always do best. This is the researching, formulation, manufacturing, and marketing of Nutranomics®and GenEpic®-branded products plus securing NNRX formulation and OEM contracts. The forces that were preventing us from this core objective were many, but can be categorized by; ineffective sales and marketing plans, misaligned staffing, lack of manufacturing cost controls, pricing models which prevented us from being competitive and finally, poor cash flows as a direct result of the conditions above. After a decade of fast-growth, NNRX plateaued and was in decline. However, at its core was a committed team of employees devoted to the Company, its brand, and its mission to provide one of the best nutraceutical product lines to a growing list of customers worldwide. With this belief, I assumed an active management role in the Company.
The day I assumed office, I dismissed underperforming staff, began scripting an employee handbook, defined job requirements and reviewed the balance of W-2 versus 1099 staff. In the weeks after, we audited our supply chain, manufacturing, inventory, pricing and reviewed credit lines for customers and our own with our creditors and banks. We cut, trimmed, streamlined and found savings never before realized. Our work resulted in significant reductions of operating costs, and in one such case, we found an available cost reduction of 30% on our leading products. We expect to realize these financial benefits and others in the coming quarters.
This was good news, but as mentioned above, if we could not leverage sales growth in this new paradigm, all the process efficiencies and cost saving measures would not benefit our shareholders. We then looked at every aspect of our product lines and their sales. We endeavored to complete a new order processing and CRM system to market, sell, deliver and service our customers. We studied customer purchasing patterns and trends in the market and engaged the Hamacher Group to update our brand and positioning for our current and future products we will launch. We negotiated an exclusive worldwide license for GenEpic® and refocused Dr. Gibbs onto OEM and formulation sales. At this moment, Dr. Gibbs is in Asia actively securing orders for our OEM and Formulation Division.
Our last 10-Q showed the decline in year-over-year sales we must reverse first and before we enter our next growth stage. This need is critical for our staff, our shareholders and our customers. For those of you who reviewed the terms of my employment contract disclosed in our recent Current Report on Form 8-K filed with the SEC, I am also staking my compensation directly on measured increases in sales. I believe the plans above will help us meet them.
Our stock has suffered over the last year. News and updates were scattered due to ongoing declines in sales to new customers and our lack of new products developed for the billion-dollar nutraceutical market in which we compete. Our stock price continually retreated due to the financing structures once available to us to pay for mandatory public market costs and listing requirements. Maintaining our listing, reporting and compliance remained important to us and critical to our shareholders. It is for this reason, I am addressing you today. We qualified and quantified each of the financings which may have dilutive effects in the future. I say "may" because it is our intent to pay them off if possible, all of them, with capital I plan to personally inject into NNRX in the coming weeks. I cannot disclose more of these details but certainly will in an 8-K and press release as appropriate.
Since we have received a number of comments and questions from shareholders on the potential action to reverse split our shares, let me provide you our insights. Our consideration of such was not a shareholder request recover additional, dilutive share issuances only to issue more shares. Rather, this consideration was an effort to position our stock to meet listing requirement on OTC Markets' QB and other National Exchanges like Nasdaq and NYSE. We believe we will obtain greater access to investors and potentially institutional investors with a cap structure and share price greater than current pricing.
This, however is down the road at best. For now, the below is our basic plan;
1. Rebuild Nutranomics' sales and communicate our efforts
2. Diminish or eliminate dilutive financing structures currently in place
3. Finance our business with new capital
4. Report our successes each step of the way
I hope this initial communication has answered many of the questions asked of us over the last two weeks. While I always want to be shareholder-responsive, I have also enlisted the help of other seasoned professionals to do the same. I will speak to all of our shareholders in consistent intervals on conference calls, press and at investor events. When not doing so, I will be out getting orders and building our business with our new sales team. For this reason, please engage with our shareholder communications contacts and others below also charged to service your questions and requests.
We value your ownership of NNRX shares and appreciate your support of the actions and plans detailed in this letter to you. We will be back in touch, and more frequently, from this point onward.
Sincerely,
Dr. Edward "Joe" Eyring, M.D.
About Nutranomics Inc.
Nutranomics, Inc. (OTC PINK: NNRX) has been at the forefront of research and development of nutritional food products since its inception in 1995. In the first years of its operations, Nutranomics provided research and development of supplement formulations and nutraceuticals for domestic and international brands. After developing 100's of successful formulations and patents, Nutranomics developed its own brand of nutraceuticals in 1997, Nutranomics®, and began to market and sell its products directly to consumers and into retail outlets. Nutranomics maintains customers in the US, Canada, Taiwan, Japan, Singapore, Malaysia, Korea and Poland.
More than just a health supplement manufacturer, Nutranomics supports the worldwide community of people aiming for a healthy lifestyle by making education a core business philosophy.
Forward-Looking Statements:
Safe Harbor: This press release contains forward-looking information within the meaning of section 27A of the Securities Act of 1933 and section 21E of the Securities Exchange Act of 1934 and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Nutranomics Inc., to be materially different from the statements made herein.
For the Company:
Matt Crowley Controller NURTANOMICS, INC. (OTC PINK : NNRX)
11487 S. 700 E
Draper, UT 84020
e: matt@nutranomics.com
p: (801) 576-8350
f: (801) 619-9060
w: www.nutranomics.com
Investor relations contact: John Mattio
Lamnia International for:
Nutranomics, Inc.
e: jmattio@lamniaintl.com
p: (203) 885-1058
w: www.lamniaintl.com
Source: Nutranomics Inc.
Be careful here with NNRX, it is a preloaded Hype and DUMP stock with no meat, just HYPE.
Make a Quick buck and Dont get stuck, good luck!
Hi Nathanial,
Have you tried PM the other Mods and ask them to resign if they're no longer interested in NNRX?
Tried to apply for Mod. Says positions full. Need some of the inactive ones to resign to open position or maybe you can email admin and see if they will delete a few.
Looks like I'm the only active Moderator right now and I can only sticky one item which I have already used. Therefore, we need a few more people to apply for the Mod spots to help sticky new items to attract new investors.
Someone sticky this one...
We, the shareholders, are in good hands.
His history alone tells me why the accumulation shot up so much the day he took position as CEO.
Edward “Joe” Eyring, II, M.D., age 48 is a previously Board-certified colorectal surgeon and successful entrepreneur in the healthcare industry with an extensive and successful record of practice and business development. By the time he entered medical school in the late 1980’s, Dr. Eyring had already spent nearly a decade apprenticing with his father, an orthopedic surgeon who treated orphaned children in developing nations. A fascination with medicine, coupled with the satisfaction of helping people in need, ignited his interest in public service.
By the time he became a licensed physician in 1994, Dr. Eyring had already learned first-hand about the calamity of disease progression in patients with limited access to preventative care or treatment. Inspired by these experiences, he embarked upon his medical career with a long-range vision toward making quality medical care affordable and accessible to anyone.
During 13 years as a colorectal surgeon, Dr. Eyring witnessed devastating results of insufficient access to preventative care or treatment. He had an opportunity to work with a naturopathic medical doctor and learned benefits of a more integrative, holistic approach to disease prevention and cure.
As a medical entrepreneur, Dr. Eyring gained first-hand knowledge of how rate structures also impacted health outcomes; those without insurance either went deeply into debt or without treatment altogether. The disparity strengthened his resolve to bridge the gap in coverage and provide equal opportunity for anyone to maintain good health.
Since 2014, Dr. Eyring has been Managing Director of Domaine Global LLC; from 2010-2013, Dr. Eyring was the Founder, CEO and Chair of Simplify Rx, Inc.; in 2013, Dr. Eyring was a Medical Director at Aeromedical Collection Services; in 2014, Dr. Eyring founded American Recovery Company, which he has operated until the present date; from 2004-2013, Dr. Eyring was the founding partner and Medical Director of Physicians Pharmaceutical Services; from 2005-2012, Dr. Eyring was the owner and principal researcher of Synergies Medical Research, LLC; from 2000-2013, Dr. Eyring was a surgeon and Founding Practice Leader at Integrative GI Healthcare; and from 2000-2012, Dr. Eyring was the sole proprietor of the Pelvic Floor Diagnostic Center in Murray, Utah.
Pursuant to Dr. Eyring’s employment contract with the Company, entered into on September 29, 2015, Dr. Eyring will be compensated in the amount of $160,000 per year, which shall be accrued until January 1, 2016. At such time, it will be paid in full or converted into Company common stock at the previous 5-day volume weighted average price at such time. As of January 1, 2016, Dr. Eyring’s annual compensation shall increase to $260,000 per year if the Company’s revenues during the October 1, 2015-December 31, 2015 period increase two-fold as compared the same period during 2014. Otherwise, his annual compensation shall remain at $160,000 per year. If his annual compensation does increase to $260,000 per year, $160,000 shall be paid in stock on a quarterly basis valued at the previous 5-day VWAP at the time of issuance, with the balance paid in cash. Dr. Eyring will also receive an additional equity award during the first year of employment equal to 0.83% of the issued and outstanding common stock of the Company following the completion of each month of employment during the first year. The employment contract is terminable at the election of either party without cause upon the provision of 30 days’ notice to the other, and is terminable by the Company for cause at any time.
Pictures of Dr. Gibbs in Japan
https://www.facebook.com/GenEpic.in.Japan/photos_stream
NNRX's Products Can Be Bought Here:
http://www.amazon.com/s/ref=sr_so_2?rh=n%3A3760901%2Ck%3ANutranomics%2Cp_89%3ANutranomics&keywords=Nutranomics&ie=UTF8&qid=1445441303
http://bodyzenbalance.com/harmony-health-services-nutranomics-products/
http://www.luckyvitamin.com/p-644852-nutranomics-viraguard-dietary-supplement-60-capsules?redirect=1
https://www.pureformulas.com/search?Ntt=Nutranomics
http://www.lazada.com.ph/nutranomics/
http://iprice.ph/nutranomics/
GenEpic PBS Special & Other Links
1) GenEpic PBS Special
Great news. Common A/S stays at 750M. This means that the CEO has already injected his money into NNRX to pay off the converters.
The new CEO is absolutely brilliant.
Nutranomics, Inc. Issues Shareholder Letter
Newly-Appointed, CEO and President, Dr. Edward "Joe" Eyring Details Immediate Actions and Improvements to Operations
DRAPER, UT -- (Marketwired) -- 10/14/15 -- Nutranomics, Inc. (OTC PINK: NNRX) ("Nutranomics" or "The Company"), a diversified nutraceutical formulator, supplement manufacturer and marketer of Nutranomics® health supplements, today issued a Shareholder Letter (the "Letter"). The Letter details challenges the Company endured during the last year, reports operational improvements to date, establishes strategies to regain sales momentum and provides options to finance the Company's growth.
Re: NNRX Shareholder Letter
Date: October 14, 2015
From: Dr. Edward "Joe" Eyring
Valued Shareholders,
I would like to acknowledge and thank those who wrote or spoke the words of support received after my appointment to CEO and President of Nutranomics, Inc. My intent is to continue to gain your trust over successive quarters as we rebuild our core business segments and reinvigorate others. I believe the plans and goals we have established as a team will result in revenue and earnings growth, an increase in the value of our stock and the ability to regain shareholders' and the market's confidence. All of these are typical CEO goals, but the skill for us to accomplish them is ultimately found in our operations as a company. For this reason, this letter focuses on this first and foremost.
As stated in the announcement last week, my work with Nutranomics included a three-month process during which time the Company provided me access to management, staff, customers, financials and suppliers. Dr. Tracy Gibbs and then Michael Doron each had solid business plans for the Company during their tenures, but I believe both gentlemen would agree that the Company's inability to achieve them detracted attention from that which Nutranomics should always do best. This is the researching, formulation, manufacturing, and marketing of Nutranomics®and GenEpic®-branded products plus securing NNRX formulation and OEM contracts. The forces that were preventing us from this core objective were many, but can be categorized by; ineffective sales and marketing plans, misaligned staffing, lack of manufacturing cost controls, pricing models which prevented us from being competitive and finally, poor cash flows as a direct result of the conditions above. After a decade of fast-growth, NNRX plateaued and was in decline. However, at its core was a committed team of employees devoted to the Company, its brand, and its mission to provide one of the best nutraceutical product lines to a growing list of customers worldwide. With this belief, I assumed an active management role in the Company.
The day I assumed office, I dismissed underperforming staff, began scripting an employee handbook, defined job requirements and reviewed the balance of W-2 versus 1099 staff. In the weeks after, we audited our supply chain, manufacturing, inventory, pricing and reviewed credit lines for customers and our own with our creditors and banks. We cut, trimmed, streamlined and found savings never before realized. Our work resulted in significant reductions of operating costs, and in one such case, we found an available cost reduction of 30% on our leading products. We expect to realize these financial benefits and others in the coming quarters.
This was good news, but as mentioned above, if we could not leverage sales growth in this new paradigm, all the process efficiencies and cost saving measures would not benefit our shareholders. We then looked at every aspect of our product lines and their sales. We endeavored to complete a new order processing and CRM system to market, sell, deliver and service our customers. We studied customer purchasing patterns and trends in the market and engaged the Hamacher Group to update our brand and positioning for our current and future products we will launch. We negotiated an exclusive worldwide license for GenEpic® and refocused Dr. Gibbs onto OEM and formulation sales. At this moment, Dr. Gibbs is in Asia actively securing orders for our OEM and Formulation Division.
Our last 10-Q showed the decline in year-over-year sales we must reverse first and before we enter our next growth stage. This need is critical for our staff, our shareholders and our customers. For those of you who reviewed the terms of my employment contract disclosed in our recent Current Report on Form 8-K filed with the SEC, I am also staking my compensation directly on measured increases in sales. I believe the plans above will help us meet them.
Our stock has suffered over the last year. News and updates were scattered due to ongoing declines in sales to new customers and our lack of new products developed for the billion-dollar nutraceutical market in which we compete. Our stock price continually retreated due to the financing structures once available to us to pay for mandatory public market costs and listing requirements. Maintaining our listing, reporting and compliance remained important to us and critical to our shareholders. It is for this reason, I am addressing you today. We qualified and quantified each of the financings which may have dilutive effects in the future. I say "may" because it is our intent to pay them off if possible, all of them, with capital I plan to personally inject into NNRX in the coming weeks. I cannot disclose more of these details but certainly will in an 8-K and press release as appropriate.
Since we have received a number of comments and questions from shareholders on the potential action to reverse split our shares, let me provide you our insights. Our consideration of such was not a shareholder request recover additional, dilutive share issuances only to issue more shares. Rather, this consideration was an effort to position our stock to meet listing requirement on OTC Markets' QB and other National Exchanges like Nasdaq and NYSE. We believe we will obtain greater access to investors and potentially institutional investors with a cap structure and share price greater than current pricing.
This, however is down the road at best. For now, the below is our basic plan;
1. Rebuild Nutranomics' sales and communicate our efforts
2. Diminish or eliminate dilutive financing structures currently in place
3. Finance our business with new capital
4. Report our successes each step of the way
I hope this initial communication has answered many of the questions asked of us over the last two weeks. While I always want to be shareholder-responsive, I have also enlisted the help of other seasoned professionals to do the same. I will speak to all of our shareholders in consistent intervals on conference calls, press and at investor events. When not doing so, I will be out getting orders and building our business with our new sales team. For this reason, please engage with our shareholder communications contacts and others below also charged to service your questions and requests.
We value your ownership of NNRX shares and appreciate your support of the actions and plans detailed in this letter to you. We will be back in touch, and more frequently, from this point onward.
Sincerely,
Dr. Edward "Joe" Eyring, M.D.
About Nutranomics Inc.
Nutranomics, Inc. (OTC PINK: NNRX) has been at the forefront of research and development of nutritional food products since its inception in 1995. In the first years of its operations, Nutranomics provided research and development of supplement formulations and nutraceuticals for domestic and international brands. After developing 100's of successful formulations and patents, Nutranomics developed its own brand of nutraceuticals in 1997, Nutranomics®, and began to market and sell its products directly to consumers and into retail outlets. Nutranomics maintains customers in the US, Canada, Taiwan, Japan, Singapore, Malaysia, Korea and Poland.
More than just a health supplement manufacturer, Nutranomics supports the worldwide community of people aiming for a healthy lifestyle by making education a core business philosophy.
Forward-Looking Statements:
Safe Harbor: This press release contains forward-looking information within the meaning of section 27A of the Securities Act of 1933 and section 21E of the Securities Exchange Act of 1934 and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Nutranomics Inc., to be materially different from the statements made herein.
For the Company:
Matt Crowley Controller NURTANOMICS, INC. (OTC PINK : NNRX)
11487 S. 700 E
Draper, UT 84020
e: matt@nutranomics.com
p: (801) 576-8350
f: (801) 619-9060
w: www.nutranomics.com
Investor relations contact: John Mattio
Lamnia International for:
Nutranomics, Inc.
e: jmattio@lamniaintl.com
p: (203) 885-1058
w: www.lamniaintl.com
Source: Nutranomics Inc.
NNRX .0011 up shes moving. 52 week high was .06 I see a lot of potential here with new game changer CEO imo.
I have no doubt NNRX can get to your projections as NNRX is a well established company with real products that being sold worldwide and bringing in real revenues with high profit margin. On top of that, the Share Structure is really low (OS=480M, AS=750M) for a trip stock. Therefore, once the news starts to flow, this can run to pennies pretty quickly.
We need to reach .05 to .10+ to buy a Ferrari!
That's because NNRX's OS is extremely low (only 480M) and big buyers don't want to cause the quick run just yet by smacking the thin asks. They wait for the sizable asks to show up to snatch them quick. It's a great strategy for loading up big.
Term Sheet news could come out at any moment. It has been almost 6 weeks since ABHI announced it.
Abhi Signs Term Sheet With Pioneer Capital
AMBICOM HOLDINGS INC ("ABHI-0") - Abhi Signs Term Sheet With Pioneer Capital
AmbiCom Holdings, Inc. announced that it has executed a term sheet for a term loan facility with Pioneer Capital of Irvine, California.
"This debt facility will give us access to up $2,500,000 in non-dilutive debt. We intend to use the proceeds to retire our convertible notes and to grow our Active Optimization business. The note is scheduled to close within six weeks," stated John Hwang, Chairman and CEO of AmbiCom Holdings, Inc.
Insiders own over 30 millions shares.
Name of Beneficial Owner (1) Amount and Nature of Beneficial Owner Percent of Class (2)
John Hwang (4) 17,000,000 32.3 %
Veloxum Corp. (3) 13,100,437 24,9 %
Robert Radoff 412,500 *
All Directors and Executive Officers as a Group (3 persons) 30,512,937 54.5 %
NNRX is a well established company with real products being sold worldwide and bringing in real revenues with high profit margin. On top of that, the Share Structure is really low (OS=480M, AS=750M) for a trip stock. Therefore, once the news starts to flow, this can run to pennies pretty quickly.
Pictures of Dr. Gibbs in Japan
https://www.facebook.com/GenEpic.in.Japan/photos_stream
At this moment, Dr. Gibbs is in Asia actively securing orders
I'm holding for pennies.
It's a new dawn, it's a new day for NNRX.
"Our stock has suffered over the last year. News and updates were scattered due to ongoing declines in sales to new customers and our lack of new products developed for the billion-dollar nutraceutical market in which we compete. Our stock price continually retreated due to the financing structures once available to us to pay for mandatory public market costs and listing requirements. Maintaining our listing, reporting and compliance remained important to us and critical to our shareholders. It is for this reason, I am addressing you today. We qualified and quantified each of the financings which may have dilutive effects in the future. I say "may" because it is our intent to pay them off if possible, all of them, with capital I plan to personally inject into NNRX in the coming weeks. I cannot disclose more of these details but certainly will in an 8-K and press release as appropriate."
Boooom shaka-la-ka!! Moving right along, new CEO is gonna rock the kasbah with revised approach for this company. $$ NNRX
Well. The 7s were gone quicker than I thought.